KalVista Pharmaceuticals Inc (NAS:KALV)
$ 11.86 -0.25 (-2.06%) Market Cap: 500.35 Mil Enterprise Value: 441.07 Mil PE Ratio: 0 PB Ratio: 4.63 GF Score: 30/100

Kalvista Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 13, 2022 / 07:00PM GMT
Release Date Price: $14.81 (+3.86%)
Serge D. Belanger
Needham & Company, LLC, Research Division - Senior Analyst

Good afternoon. I'm Serge Belanger, one of the health care analysts at Needham. I want to welcome you to the 21st Annual Needham Healthcare Conference. We're happy to have for our next session KalVista Pharmaceuticals, one of the pure-play HAE story. They are seeking to address both the acute and prophylactic segment of the HAE space, both with oral products as well as new mechanisms of action. So today with us, we have Andy Crockett, the CEO; Ben Palleiko, CFO; and Chris Yea, the Chief Development Officer of the company.

So I'll hand it over to Andy to give us a brief overview of the company, then we'll proceed to Q&A. And for those listening online, there is an option to submit questions via the portal. I'll be checking that as we move to the Q&A portion of the presentation. So Andy, please take it away.

Thomas Andrew Crockett
KalVista Pharmaceuticals, Inc. - CEO & Director

Thanks, Serge, for having us. Happy to be here today. Just as an overview, we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot